List of Small Molecule Pharmaceuticals Companies in Utah - 15

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

Curza is a small molecule therapeutics development company. Curza has developed a new class of antibiotics that are active and selective against Gram-negative pathogens.

Dyad Labs (A Mérieux NutriSciences Company) is an ISO/IEC 17025:2017 accredited contract laboratory providing specialized chemistry and microbiology testing services to the Nutraceutical and Food & Beverage industries since 2008. Dyad Labs’ mission is to professionally, effectively, and ethically perform testing for our customers to produce accurate and precise results while offering exceptional customer service and support by meeting and exceeding customer expectations. Led by a management team of experts that have diverse backgrounds in pharmaceutical, nutraceutical, and bioanalytical research fields, Dyad Labs is constantly working on new technologies that offer cutting edge solutions to increasing regulatory requirements and calls for full transparency of the supply chain.

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

JSK’s Therapeutics’ mission is to aggressively develop JSK to treat multiple types of cancer. We seek to position JSK as a leader in the evolving field of NO therapeutics for cancer treatment and co-therapeutic use as appropriate.

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

MasterControl is on a mission to bring life-changing products to more people sooner. Everything we do is designed to help you develop, manufacture, and commercialize products that help people live longer, healthier, and more enjoyable lives. We offer the world's leading solution for product quality, helping highly regulated companies ensure quality and compliance in their life sciences operations. Our quality management system is the most established and used QMS in the industry and is used by the FDA, CDC, and ORA. And our digital manufacturing solution offers errorless and frictionless production by taking you 100% paperless on your shop floor. The results speak for themselves. MasterControl customers enjoy 80% faster post-production review times, 21% fewer deviations, and 100% right-first-time. There's a reason more than 1,000 global customers have used MasterControl to bring more than 250,000 life-changing products to market. Learn more today at mastercontrol.com.

Nelson Labs is a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. Nelson Labs serves over 3,500 customers across 15 facilities in the United States, Mexico, Asia, and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Learn more about Nelson Labs at www.nelsonlabs.com. Safeguarding Global Health® - with every test we complete.

NuView Life Sciences is a clinical stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView's NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo of confirmation of cancer. The NV-VPAC1 agent can be utilized to deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.

Over the course of millions of years, nature evolved to create the world’s most awe-inspiring, life-changing health outcomes. Peel Therapeutics translates these evolutionary outliers to develop medicines for patients with cancer and inflammatory diseases. Using scientific and medical expertise, state-of-the-art technology and drug development knowledge, we redesign what nature offers into medicines for patients by tackling solubility, scalability, and bioavailability. Our clinical stage therapeutic pipeline treats a spectrum of devastating conditions, with a near-term focus on cancer and inflammation. At Peel Therapeutics, we push the limits of biology to develop highly effective and safe medicines for patients that transcend the incremental.

Phoenix PharmaLabs, Inc. (PPL) is a privately held preclinical drug discovery company focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. PPL was founded in 2002 with the mission of bringing its new class of opioid pain therapies and addiction treatment to market. PPL has designed a novel family of ligands with high binding affinity at all three opiate receptors: mu, kappa and delta. These unique ligands, derived from opioid backbones using proprietary technology, have more balanced receptor activity than morphine and other opioids, with partial agonist / antagonist activity at mu, relatively higher, but not full, kappa agonist activity, and moderate delta activity. This profile results in first-ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects. Studies of the drugs have been conducted by prominent scientists at leading institutions including Virginia Commonwealth University (VCU), the University of Michigan, SRI International and Torrey Pines Institute for Molecular Studies. Study results in rodents and monkeys performed by the National Institutes of Health (NIH) and SRI International Laboratories demonstrated the following: • Robust analgesic potency (8x - 60x stronger than morphine) • No dangerous narcotic effects • No signs of respiratory depression - at over 150x dosage • No death from overdose - even at 350x dosage • No physical dependence in naive rodents • Little or no abuse potential in monkeys • No dysphoria in monkeys • No inhibition of GI transport in rodents - even at 350x dosage • No significant diuresis in rodents • Does not precipitate withdrawal in dependent monkeys Since the drugs do not precipitate withdrawal, they offer very promising use for addiction therapy as a preferred substitute for methadone and buprenorphine.

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Spriaso is a biopharmaceutical company dedicated to improving therapeutics through innovative patient friendly product options. Spriaso has several candidates in development with a focus on the central nervous system (CNS) and gastrointestinal (GI) disorders. Our portfolio of unique products have successfully completed proof of principle clinical studies. In addition, Spriaso develops ANDA products and has received an FDA approved NDA. These products are available for out-license to a marketing partner and are protected by multiple issued and pending patents.

Tekholding is a research and development company driving sustainable innovation across diverse sectors including, healthcare, sustainable energy, and materials. With a focus on innovation at every stage, we are committed to advancing solutions that drive positive change and long-term viability in these essential fields.